V
Vita Fedele
Researcher at Structural Genomics Consortium
Publications - 5
Citations - 475
Vita Fedele is an academic researcher from Structural Genomics Consortium. The author has contributed to research in topics: Kinase & Bromodomain. The author has an hindex of 5, co-authored 5 publications receiving 376 citations. Previous affiliations of Vita Fedele include Novo Nordisk & University of Oxford.
Papers
More filters
Journal ArticleDOI
Comprehensive characterization of the Published Kinase Inhibitor Set
Jonathan M. Elkins,Vita Fedele,M. Szklarz,Kamal R. Abdul Azeez,Eidarus Salah,Jowita Mikolajczyk,Sergei Romanov,Nikolai Sepetov,Xi Ping Huang,Bryan L. Roth,Ayman Al Haj Zen,Denis Fourches,Eugene N. Muratov,Alexander Tropsha,Joel Morris,Beverly A. Teicher,Mark Kunkel,Eric C. Polley,Karen Lackey,Francis Atkinson,John P. Overington,John P. Overington,Paul Bamborough,Susanne Müller,Daniel J. Price,Timothy M. Willson,Timothy M. Willson,David H. Drewry,David H. Drewry,Stefan Knapp,Stefan Knapp,William J. Zuercher,William J. Zuercher +32 more
TL;DR: A thorough characterization of the Published Kinase Inhibitor Set is provided and chemical starting points for designing new chemical probes of orphan kinases are identified and the utility of these leads are illustrated by developing a selective inhibitor for the previously untargeted kinases LOK and SLK.
Journal ArticleDOI
Identification of a Chemical Probe for Family VIII Bromodomains Through Optimization of a Fragment Hit
Brian S. Gerstenberger,John David Trzupek,Cynthia Tallant,Cynthia Tallant,Oleg Fedorov,Oleg Fedorov,Panagis Filippakopoulos,Panagis Filippakopoulos,Paul Brennan,Paul Brennan,Vita Fedele,Vita Fedele,Sarah Martin,Sarah Martin,Sarah Picaud,Sarah Picaud,Catherine Rogers,Catherine Rogers,Mihir D. Parikh,Alexandria P. Taylor,Brian Samas,Alison O'Mahony,Ellen L. Berg,Gabriel Pallares,Adam D. Torrey,Daniel K. Treiber,Ivan J. Samardjiev,Brian T. Nasipak,Teresita Padilla-Benavides,Qiong Wu,Anthony N. Imbalzano,Jeffrey A. Nickerson,Mark E. Bunnage,Susanne Müller,Susanne Müller,Stefan Knapp,Stefan Knapp,Stefan Knapp,Dafydd R. Owen +38 more
TL;DR: The high specificity of PFI-3 for family VIII was achieved through a novel bromodomain binding mode of a phenolic headgroup that led to the unusual displacement of water molecules that are generally retained by most other bromidomain inhibitors reported to date.
Journal ArticleDOI
Hypoxia induces a lipogenic cancer cell phenotype via HIF1α-dependent and -independent pathways.
Alessandro Valli,Miguel A. Rodríguez,Loukas Moutsianas,Roman Fischer,Vita Fedele,Hong Lei Huang,Ruud G.P.M. van Stiphout,Dylan Marc Jones,Michael T. McCarthy,Maria Vinaxia,Kaori Igarashi,Maya Sato,Tomoyoshi Soga,Francesca M. Buffa,James S. O. McCullagh,Oscar Yanes,Adrian L. Harris,Benedikt M. Kessler +17 more
TL;DR: The results demonstrate the impact of hypoxia on lipid metabolites, of which a distinct subset is regulated by HIF1α, which is one of the principal regulators of metabolism and energetic balance in cancer cells.
Journal ArticleDOI
Selective Targeting of Bromodomains of the Bromodomain-PHD Fingers Family Impairs Osteoclast Differentiation.
Julia Meier,Cynthia Tallant,Oleg Fedorov,Hanna Witwicka,Sung-Yong Hwang,Ruud G.P.M. van Stiphout,Jean-Philippe Lambert,Catherine Rogers,Clarence Yapp,Brian S. Gerstenberger,Vita Fedele,Pavel Savitsky,David Heidenreich,Danette L. Daniels,Dafydd R. Owen,Paul V. Fish,Niall Igoe,Elliott D. Bayle,Bernard Haendler,Udo Oppermann,Francesca M. Buffa,Paul Brennan,Susanne Müller,Anne-Claude Gingras,Anne-Claude Gingras,Paul R. Odgren,Mark J. Birnbaum,Stefan Knapp +27 more
TL;DR: The data suggest a key role of BRPF in regulating gene expression during osteoclastogenesis, and the excellent druggability of these bromodomains may lead to new treatment strategies for patients suffering from bone loss or osteolytic malignant bone lesions.
Journal ArticleDOI
Identification of molecular targets for the targeted treatment of gastric cancer using dasatinib
Raquel Carvalho Montenegro,Alison Howarth,Alessandro Ceroni,Vita Fedele,Batoul Farran,Felipe Pantoja Mesquita,Martin Frejno,Benedict-Tilman Berger,Benedict-Tilman Berger,Stephanie Heinzlmeir,Stephanie Heinzlmeir,Heba Z. Sailem,Roberta Tesch,Roberta Tesch,Daniel Ebner,Stefan Knapp,Stefan Knapp,Rommel Mario Rodriguez Burbano,Bernhard Kuster,Bernhard Kuster,Susanne Müller +20 more
TL;DR: The data suggest dasatinib for treatment of GC based on its unique property, inhibiting a small number of key kinases (SRC, FRK, DDR1 and SIK2), highly expressed in GC patients.